NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Price, News & Analysis $1.95 -0.10 (-4.88%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.88▼$2.0550-Day Range$1.69▼$2.5352-Week Range$1.55▼$4.42Volume37,533 shsAverage Volume239,212 shsMarket Capitalization$4.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Lixte Biotechnology alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Lixte Biotechnology Stock (NASDAQ:LIXT)Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Read More LIXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIXT Stock News HeadlinesSeptember 4, 2024 | globenewswire.comLIXTE Receives U.S. Patent Issue Notification for Immune OncologyAugust 31, 2024 | americanbankingnews.comLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Up 20.0% in AugustSeptember 8, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 26, 2024 | finance.yahoo.comFirst Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | globenewswire.comFirst Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 19, 2024 | globenewswire.comLIXTE Biotechnology Provides Update On Recent Activities and DevelopmentsAugust 16, 2024 | investorplace.comLIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024August 15, 2024 | globenewswire.comLIXTE Biotechnology Holdings to Present at Two Investor ConferencesSeptember 8, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.June 14, 2024 | globenewswire.comLIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialJune 14, 2024 | globenewswire.comLIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialJune 6, 2024 | globenewswire.comScientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemJune 3, 2024 | globenewswire.comLIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerMay 20, 2024 | finanznachrichten.deLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Provides Update on Recent ActivitiesMay 20, 2024 | globenewswire.comLIXTE Biotechnology Holdings Provides Update on Recent ActivitiesMay 8, 2024 | globenewswire.comLIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”April 24, 2024 | theglobeandmail.comMixed Shelf Filing Gives Micro Cap Delayed BoostMarch 29, 2024 | stockhouse.comNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESSee More Headlines Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/08/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIXT CUSIPN/A CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-5,562.77% Return on Assets-102.10% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.56) per share Price / Book-3.48Miscellaneous Outstanding Shares2,249,000Free Float1,900,000Market Cap$4.39 million OptionableNot Optionable Beta-0.16 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Bastiaan van der Baan M.Sc. (Age 52)President, CEO & Chairman of the Board of Directors Comp: $172.78kMr. Robert Neal Weingarten (Age 72)VP & CFO Comp: $175kMr. Eric J. Forman J.D. (Age 45)VP & COO Comp: $200kDr. James S. Miser M.D. (Age 77)Chief Medical Officer Comp: $175kKey CompetitorsAlzamend NeuroNASDAQ:ALZNNRx PharmaceuticalsNASDAQ:NRXPGuardion Health SciencesNASDAQ:GHSISynlogicNASDAQ:SYBXKALA BIONASDAQ:KALAView All CompetitorsInsidersDer Baan Bastiaan Jeroen VanBought 10,000 shares on 10/3/2023Total: $28,000.00 ($2.80/share)View All Insider Transactions LIXT Stock Analysis - Frequently Asked Questions How have LIXT shares performed this year? Lixte Biotechnology's stock was trading at $2.35 at the beginning of 2024. Since then, LIXT shares have decreased by 17.0% and is now trading at $1.95. View the best growth stocks for 2024 here. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.45) earnings per share for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology's stock reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? Lixte Biotechnology (LIXT) raised $7 million in an initial public offering on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIXT) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIXT Stock Alerts